Chorea: Clinical Trials

16 trials for Chorea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 16 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 16
Phase 21Completed 1

Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Placebo, Valbenazine - Dyskinesia, Cerebral Palsy
Phase 3CompletedNeurocrine Biosciences862022-04-152026-04-29
TEsting METformin Against Cognitive Decline in HD
Metformin, Placebo - Huntington Disease
Phase 3CompletedInstituto de Investigacion Sanitaria La Fe602022-04-112025-09-25
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Pridopidine, Placebo - Huntington Disease
Phase 3CompletedPrilenia4992020-10-162025-03-12
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Valbenazine, Placebo - Chorea, Huntington
Phase 3CompletedNeurocrine Biosciences1282019-11-132023-10-11
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo - Huntington Disease, Irritability
Phase 3CompletedThe University of Texas Health Science Center, Houston202019-08-052024-01-05
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
RO7234292 (RG6042) - Huntington Disease
Phase 3CompletedHoffmann-La Roche2362019-04-232023-08-31
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
RO7234292, Placebo - Huntingtons Disease
Phase 3CompletedHoffmann-La Roche8992019-01-232024-03-01
Alternatives for Reducing Chorea in Huntington Disease
SD-809 - Chorea Associated With Huntington Disease
Phase 3CompletedAuspex Pharmaceuticals, Inc.1192013-11-122021-11-09
First Time Use of SD-809 in Huntington Disease
SD-809, Placebo - Chorea
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.902013-08-052017-09-20
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Dimebon, Placebo - Huntington Disease
Phase 3CompletedMedivation, Inc.4032009-07-012016-10-12
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Olanzapine, Xenazine, Tiapridal - Huntington Disease
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1802009-04-012018-01-19
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
ACR16, Placebo - Huntington's Disease
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.4372008-04-242023-08-29
Pilot Study of Minocycline in Huntington's Disease
minocycline, Matching placebo - Huntington Disease
Phase 2 / Phase 3CompletedMerit Cudkowicz1142006-04-012013-04-19
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
Ethyl-EPA (Miraxion™) - Huntington Disease
Phase 3CompletedAmarin Neuroscience Ltd3002005-09-012007-12-27
Riluzole in Huntington's Disease
Riluzole - Huntington Disease
Phase 3CompletedSanofi5371999-11-012012-02-17
Efficacy and Safety of Tetrabenazine in Chorea
tetrabenazine or placebo - Huntington's Disease
Phase 3CompletedPrestwick Pharmaceuticals2005-09-22

Narrower conditions

Huntington Disease (14)  ·  Athetosis (1)  ·  Cerebral Palsy (1)  ·  Dyskinesias (1)  ·  Dystonia (1)  ·  Lymphoma, Follicular (1)  ·  Movement Disorders (1)

Broader conditions

Central Nervous System Diseases (16)  ·  Nervous System Diseases (16)  ·  Brain Diseases (15)  ·  Dyskinesias (15)  ·  Movement Disorders (15)  ·  Basal Ganglia Diseases (14)  ·  Cognition Disorders (14)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Dementia (14)  ·  Genetic Diseases, Inborn (14)  ·  Heredodegenerative Disorders, Nervous System (14)  ·  Mental Disorders (14)  ·  Neurocognitive Disorders (14)  ·  Neurodegenerative Diseases (14)

Interventions

Tetrabenazine (2)  ·  deutetrabenazine (2)  ·  pridopidine (2)  ·  tominersen (2)  ·  valbenazine (2)  ·  Biguanides (1)  ·  Dextromethorphan (1)  ·  Docosahexaenoic Acids (1)  ·  Hypoglycemic Agents (1)  ·  Metformin (1)  ·  Minocycline (1)  ·  Olanzapine (1)  ·  Quinidine (1)  ·  Riluzole (1)  ·  Tiapride Hydrochloride (1)

Sponsors

Hoffmann-La Roche (2)  ·  Neurocrine Biosciences (2)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (2)  ·  Amarin Neuroscience Ltd (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Auspex Pharmaceuticals, Inc. (1)  ·  Instituto de Investigacion Sanitaria La Fe (1)  ·  Medivation, Inc. (1)  ·  Merit Cudkowicz (1)  ·  Prestwick Pharmaceuticals (1)  ·  Prilenia (1)  ·  Sanofi (1)  ·  The University of Texas Health Science Center, Houston (1)

Countries

United States (11)  ·  Canada (9)  ·  Spain (6)  ·  Germany (5)  ·  Italy (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Austria (4)  ·  France (4)  ·  Netherlands (3)  ·  Poland (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Denmark (2)  ·  Portugal (2)

Top investigators

Blair Leavitt, MD (1)  ·  Christopher Ross, MD, PhD (1)  ·  Erin L Furr Stimming, MD (1)  ·  Fred Marshall, M.D. (1)  ·  Ira Shoulson, MD (1)  ·  Merit E. Cudkowicz, MD (1)  ·  Yael Cohen (1)

Results publications

PMID 28265459, PMID 38557959, PMID 39825184, PMID 19064745, PMID 20021666, PMID 22071279, PMID 23108692, PMID 26714284, PMID 27380342, PMID 29480210, PMID 30776019, PMID 31381524, PMID 32250312, PMID 36242718, PMID 36811812, PMID 37210099, PMID 40913168, PMID 41499296, PMID 42032152

NIH funding

2018 (1)